Trofinetide: Physiology and What Research Reports
Trofinetide is a synthetic analogue of glypromate, a tripeptide fragment derived from insulin-like growth factor 1 (IGF-1). It was developed as an oral liquid for Rett syndrome, a neurodevelopmental disorder linked to MECP2 mutations, and became the first drug approved for that condition in 2023. Published phase 3 and open-label extension studies reported changes on caregiver- and clinician-rated scales, while diarrhoea and vomiting were the most commonly reported adverse events across trials and pharmacovigilance analyses.
Trofinetide is a small synthetic peptide analogue that entered the clinical literature as a candidate treatment for Rett syndrome. It is one of the relatively few peptide-derived molecules to move through randomised controlled trials to regulatory approval, which is why it appears frequently in discussions of peptide pharmacology. This page summarises what published studies describe about its origin, its proposed biology, how it has been measured, and what trial and post-marketing reports have documented. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question.
What Trofinetide Is
Trofinetide is a synthetic analogue of glycine-proline-glutamate (GPE, or glypromate), the N-terminal tripeptide that is cleaved enzymatically from insulin-like growth factor 1 (IGF-1) in tissue. The native tripeptide is short-lived; trofinetide was engineered as a more metabolically stable derivative suitable for oral administration. A drug-profile review described trofinetide as the first therapy approved for Rett syndrome, granted approval in the United States in March 2023 as an oral solution for patients aged two years and older (PMID 37191913).
Because trofinetide derives from an endogenous growth-factor fragment rather than being a hormone analogue in its own right, it is usually classified as a peptide-derived small molecule rather than a receptor agonist with a single named target.
Where the parent peptide comes from
IGF-1 is produced predominantly in the liver under growth hormone stimulation, with local paracrine production in brain, muscle and other tissues. Within the central nervous system, proteolytic processing of IGF-1 releases the GPE tripeptide. A development-focused review of trofinetide traced this lineage and described the rationale for targeting IGF-1–related signalling in Rett syndrome, where synaptic maturation and glial function are disrupted (PMID 39525048).
What It Is Proposed to Do in the Body
The mechanistic account that appears across reviews centres on neuroinflammation and synaptic biology rather than on a classical receptor. The design-and-development review of trofinetide described proposed actions on glial reactivity, dendritic and synaptic maturation, and inflammatory signalling in the central nervous system as the basis for its use in Rett syndrome (PMID 39525048). The first-approval profile likewise summarised trofinetide's development pathway from the IGF-1 tripeptide through to approval for Rett syndrome (PMID 37191913).
Preclinical work has extended beyond Rett syndrome. A 2025 animal study reported that trofinetide improved cognitive performance in APP/PS1 transgenic mice, a model of Alzheimer-type amyloid pathology, and attributed the effect to suppression of inflammation and apoptosis (PMID 41269410). That work was in mice and does not describe human outcomes.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow Trofinetide Is Studied and Measured
Research on trofinetide has used three main approaches: randomised controlled trials with caregiver- and clinician-rated scales, open-label extension studies for longer-term observation, and pharmacokinetic modelling.
Clinical endpoints
The pivotal phase 3 trial, LAVENDER, was a randomised study in girls and women with Rett syndrome; researchers reported that trofinetide produced improvement versus placebo on the Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression–Improvement scale over a 12-week treatment period (PMID 37291210). These two co-primary endpoints — one caregiver-reported, one clinician-rated — have since anchored most subsequent analyses.
Open-label extensions
The LILAC open-label extension followed participants who completed the double-blind trial, and the published results described continued treatment with maintenance of effect on the same rating scales alongside the safety profile observed in the controlled study (PMID 38917793). A second extension, LILAC-2, reported long-term safety and efficacy over a 32-month open-label period (PMID 39025065).
Pharmacokinetic modelling
Because trofinetide is dosed by body weight in a population that includes young children, exposure modelling has been a significant part of the literature. An exposure–response efficacy analysis was published to support trofinetide dosing in individuals with Rett syndrome by relating plasma exposure to change on the efficacy scales (PMID 38363467). A separate population pharmacokinetic analysis characterised trofinetide exposure in a paediatric population aged 2–4 years with Rett syndrome (PMID 39692837). An in silico physiologically based pharmacokinetic model examined the effect of hepatic impairment on trofinetide exposures (PMID 38963587).
| Study type | What researchers examined | Citation |
|---|---|---|
| Randomised phase 3 | Behaviour questionnaire and clinical global impression over 12 weeks | PMID 37291210 |
| Open-label extension | Continued efficacy and safety after the controlled trial | PMID 38917793 |
| Long-term extension | 32-month open-label safety and efficacy | PMID 39025065 |
| Meta-analysis | Pooled efficacy and safety across randomised trials | PMID 38521908 |
| Pharmacovigilance | Real-world paediatric adverse-event reports | PMID 40849266 |
Adverse Events: What Studies Report
Tolerability findings have been consistent across the trial programme. In the randomised phase 3 study, researchers reported that diarrhoea and vomiting were the most common adverse events among participants receiving trofinetide (PMID 37291210). The open-label extension reported a safety profile consistent with the double-blind trial, with diarrhoea and vomiting again the most frequently observed events (PMID 38917793), and the 32-month LILAC-2 study reported long-term safety data in the same direction (PMID 39025065).
Pooled analyses reached similar conclusions. A systematic review and meta-analysis of randomised controlled trials reported that trofinetide was associated with a higher incidence of gastrointestinal adverse events, particularly diarrhoea and vomiting, compared with placebo (PMID 38521908). A separate meta-analysis of efficacy and safety in patients with Rett syndrome reported comparable patterns (PMID 38771525). A 2025 real-world post-marketing pharmacovigilance analysis examined safety signals in the paediatric Rett syndrome population outside the trial setting (PMID 40849266).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appWhy It Matters in Peptide Literature
Trofinetide is often cited as a case study for how an endogenous peptide fragment can be chemically modified for stability and taken through formal trials. Three features stand out in the published record: the molecule originates from IGF-1 processing rather than being an IGF-1 mimetic; its clinical evidence base rests on caregiver- and clinician-rated behavioural scales rather than biomarkers; and its exposure is characterised through modelling in weight-banded paediatric populations (PMID 38363467, PMID 39692837).
Readers encountering the term outside a Rett syndrome context should note that the approved indication described in the literature is narrow (PMID 37191913), and that other applications such as the mouse Alzheimer model remain preclinical (PMID 41269410).
References
- Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study (Nature Medicine, 2023)
- Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study (Med, 2024)
- Trofinetide: First Approval (Drugs, 2023)
- Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study (Med, 2024)
- Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model (Advances in Therapy, 2024)
- Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy (Drug Design, Development and Therapy, 2024)
- A meta-analysis of the efficacy and safety of trofinetide in patients with Rett syndrome (Neurological Sciences, 2024)
- Safety Profiles of Trofinetide in Pediatric Rett Syndrome Population: A Real-World Postmarketing Pharmacovigilance Analysis (Clinical Therapeutics, 2025)
- Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials (BMC Pediatrics, 2024)
- Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome (Advances in Therapy, 2024)
- Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis (Molecular Neurobiology, 2025)
- Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome (Advances in Therapy, 2025)
Frequently asked questions
What is trofinetide?▾
Trofinetide is a synthetic analogue of glypromate, the glycine-proline-glutamate tripeptide derived from insulin-like growth factor 1. A drug-profile review described it as the first therapy approved for Rett syndrome, approved in the United States in 2023 as an oral solution for patients aged two years and older (PMID 37191913). Its development rationale centred on IGF-1-related signalling in the central nervous system (PMID 39525048).
What adverse events did trials report?▾
In the randomised phase 3 study, researchers reported diarrhoea and vomiting as the most common adverse events with trofinetide (PMID 37291210). The open-label extension reported a consistent safety profile (PMID 38917793), and a systematic review and meta-analysis of randomised trials reported a higher incidence of gastrointestinal adverse events, chiefly diarrhoea and vomiting, versus placebo (PMID 38521908).
What did the phase 3 study measure?▾
The phase 3 LAVENDER study used two co-primary endpoints: the Rett Syndrome Behaviour Questionnaire, completed by caregivers, and the Clinical Global Impression–Improvement scale, rated by clinicians. Researchers reported improvement versus placebo on both measures over a 12-week treatment period in girls and women with Rett syndrome (PMID 37291210).
Has trofinetide been studied beyond Rett syndrome?▾
Published human trials have focused on Rett syndrome. In preclinical work, a 2025 study reported that trofinetide improved cognitive function in APP/PS1 transgenic mice, an amyloid model, and linked the effect to suppression of inflammation and apoptosis (PMID 41269410). That finding was in animals and does not describe outcomes in people.
How has long-term use been studied?▾
Open-label extension studies followed trial participants after the double-blind period. The LILAC study reported continued treatment outcomes and safety consistent with the controlled trial (PMID 38917793), and the LILAC-2 study reported long-term safety and efficacy results over a 32-month open-label period (PMID 39025065).
What pharmacokinetic work has been published?▾
An exposure–response efficacy analysis related plasma exposure to efficacy-scale change to support dosing in individuals with Rett syndrome (PMID 38363467). A population pharmacokinetic analysis characterised exposure in children aged 2–4 years (PMID 39692837), and an in silico physiologically based model examined how hepatic impairment affects trofinetide exposures (PMID 38963587).
What do real-world safety analyses show?▾
A 2025 post-marketing pharmacovigilance analysis examined safety signals for trofinetide in the paediatric Rett syndrome population outside the controlled trial setting (PMID 40849266). Pooled trial data from a separate meta-analysis of efficacy and safety in Rett syndrome reported patterns consistent with the randomised studies (PMID 38771525). This information is educational, not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.